Collegium Pharmaceutical, Inc. COLL
24.71 USD +0.50 (+2.07%)
At closeNov 10, 2026, 4:03 AM EST
24.20 -0.51 -2.06%
Pre-market · Nov 10, 4:03 AM ET
24.28 Day range 25.09
21.43 52-week range 50.79
- YTD
- -46.63%
- 1 year
- -41.58%
News
seekingalpha.com Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director…
benzinga.com Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28 Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.
benzinga.com Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44 Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $46 to $44.
zacks.com Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.
benzinga.com Collegium Pharmaceutical Q3 2026 Earnings Call Transcript Collegium Pharmaceutical (NASDAQ:COLL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $825.000M-$855.000M vs $835.780M Est Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $825.000 million-$855.000 million to $825.000 million-$855.000 million vs $835.780 million estimate.- benzinga.com Collegium Pharmaceutical Q3 Adj. EPS $1.96 Beats $1.86 Estimate, Sales $216.339M Miss $217.276M Estimate Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.86 by 5.38 percent. This is a 12.89 percent decrease over…
globenewswire.com Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS…
zacks.com COLL or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks…
benzinga.com Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement As previously disclosed, Collegium Pharmaceutical, Inc. (the "Company") is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH ("Grünenthal") (as amended, the